40 results about "Ambroxol" patented technology

The application provides an ambroxol oral dissolving film composition, a preparation method and application thereof. The ambroxol oral dissolving film composition comprises an active drug, a film forming material and a taste masking agent, and the active drug is 2-amino-3,5-dibromo-N-(trans-4-hydroxycyclohexyl) benzylamine and / or a pharmaceutically acceptable salt thereof, for example, ambroxol hydrochloride. The ambroxol oral dissolving film composition provided by the application has the advantages of thin thickness, good taste, stable properties, immediate dissolution in the oral cavity without drinking water, and fast oral absorption speed. Moreover, the ambroxol oral dissolving film composition has the advantages of simple process, high drug loading, good drug content uniformity, and good market prospect.

The invention discloses an ambroxol hydrochloride preparation composition and a preparation method thereof, the ambroxol hydrochloride preparation composition contains hydroxyethyl cellulose, and the weight-average molecular weight of the hydroxyethyl cellulose is selected from 900000 to 1100000. By improving the prescription raw materials and the prescription process, the production equipment requirement and cost are greatly reduced while the product quality is ensured, and the preparation method is very suitable for large-scale industrial production.

The invention discloses a production process of an ambroxol oral solution, and belongs to the technical field of chemical medicinal preparations, the production process comprises the following steps: adding an aqueous solution containing ambroxol hydrochloride, clenbuterol hydrochloride, sorbitol, propylene glycol, glycerol, hydroxyethyl cellulose, DL-tartaric acid and sodium benzoate into a reaction kettle, and uniformly stirring to obtain the ambroxol hydrochloride oral solution, the clenbuterol hydrochloride, the sorbitol, the propylene glycol, the glycerol, the hydroxyethyl cellulose, the DL-tartaric acid and the sodium benzoate; the preparation method comprises the following steps: preparing in a production system passivated by hydroxyethyl diamine tetraacetic acid trisodium salt, treating by a two-stage series hollow membrane contactor, and finally filling a glass bottle with a liquid medicine. According to the preparation method disclosed by the invention, on the basis of prescription adjustment without adding antioxidants such as sodium pyrosulfite and the like, the impurities of the medicine in the production and storage processes are obviously reduced, the product stability and the clinical medication safety are improved, and the preparation process is simple and stable to operate and suitable for industrial production.

The invention relates to solid compositions and methods of manufacture. The present invention addresses the problem of providing a solid composition which contains at least one component selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof, and another component, and in which changes in properties are suppressed. [Solution] A solid composition containing the following components: (A) at least one substance selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof; (B) fructose; and (C) one or more components selected from the group consisting of: (C-1) vitamin B1 and vitamin C; (C-2) Chinese herbaceous peony, liquorice and valerian; (C-3) bromhexine, ambroxol, tepiperidine, salts thereof, and hydrates thereof; (C-4) clomastine, salts thereof, and hydrates thereof; and (C-5) dextromethorphan, salts thereof, and hydrates thereof.

The invention provides a method for determining the content of clenbuterol hydrochloride in an ambroxol oral solution, which comprises the following steps: respectively injecting a diluent, a reference solution and a test solution into a two-dimensional high performance liquid chromatograph, recording chromatograms, and calculating the content of clenbuterol hydrochloride by peak area according to an external standard method. The first-dimensional liquid chromatography conditions are as follows: a phosphoric acid buffer solution-methanol-acetonitrile is taken as a mobile phase A, methanol is taken as a mobile phase B, and gradient elution is carried out; the second-dimensional liquid chromatography conditions are as follows: phosphoric acid buffer solution-methanol-acetonitrile is taken as a mobile phase A, and switching is performed according to a specific program. The detection method disclosed by the invention is simple and convenient, the interference of a matrix in a sample can be well solved, the peak area response of a main component can be increased by about 5 times compared with that of a common high-performance liquid phase, and the detection limit is as low as 0.02 mu g / ml; the method is good in system applicability, good in specificity, good in repeatability, high in accuracy and good in solution stability, and can be used for quantitatively detecting the content of clenbuterol hydrochloride in the medicine.

The present application relates to the technical field of nucleic acid extraction and purification, and particularly relates to a DNA and RNA co-extraction reaction reagent and an extraction method, the reaction reagent comprising a nucleic acid protective agent RP, a sample lysis and binding liquid LB, a protein washing liquid WB1, a nucleic acid rinsing liquid WB2, and a nucleic acid elution liquid EB; the nucleic acid protective agent RP comprising DTT, mercaptoethanol, TCEP, and sodium hydroxide; the sample lysis and binding liquid LB comprising Tris-HCl, benzenesulfonic acid, sodium citrate, guanidine hydrochloride, guanidine isothiocyanate, guanidine thiocyanate, urea, triton X-100, SDS, potassium chloride, sodium chloride, bromhexine, N-acetylcysteine, ambroxol hydrochloride, isopropyl alcohol, and anhydrous ethanol; the protein washing liquid WB1 comprising Tris-HCl, benzenesulfonic acid, sodium citrate, guanidine hydrochloride, guanidine isothiocyanate, guanidine thiocyanate, urea, triton X-100, sodium chloride, isopropyl alcohol, and anhydrous ethanol; the nucleic acid rinsing liquid WB2 comprising Tris-HCl, sodium chloride, isopropyl alcohol, and anhydrous ethanol; and the nucleic acid elution liquid EB being nuclease-free water; the reagent can rapidly and fully enrich and purify DNA and RNA of a sample simultaneously.

The invention provides a method for detecting clenbuterol hydrochloride by removing hydroxyethyl cellulose in an ambroxol oral solution. According to the present invention, the high performance liquid chromatography is adopted, the HEC can form the precipitate capable of being centrifugally separated by using the acetonitrile-isopropanol mixed solvent, the interference source of the HEC is directly completely removed through the simple liquid-solid separation, the content of the clenbuterol hydrochloride is not affected, the viscosity of the test solution is equivalent to the viscosity of the mobile phase, and the detection result is accurate. According to the method, the chromatographic column is fundamentally prevented from being blocked and polluted, the service life of the chromatographic column is prolonged, a protection column is not needed, the cost is saved, the viscosity of a sample is reduced, the peak area of the clenbuterol hydrochloride is large, and the repeatability is obviously improved. The method is high in specificity, high in linearity, accuracy and precision and good in durability.

In certain embodiments, liquid formulations for oral administration are disclosed, comprising an amphiphilic material and ambroxol or a pharmaceutically acceptable salt thereof.

1. The name of the design product: packaging box (ambroxol hydrochloride oral solution). 2. The use of the design product: for product packaging. 3. The design points of the design product: in the combination of shape and pattern. 4. The picture or photo that best indicates the design points: front view.

The invention provides a polypeptide coupling medicine and application thereof. The polypeptide coupling medicine comprises antiviral polypeptide, connecting polypeptide, amino acid and ambroxol which are connected in sequence. The polypeptide coupling drug provided by the invention is obtained by coupling a coronavirus membrane fusion inhibitor and ambroxol, and is formed by coupling polypeptide serving as a targeting carrier and a load drug through a connexon via a covalent bond. Through polypeptide coupled drug activity evaluation and pharmacokinetic research, evaluation of activity changes of polypeptide and ambroxol and research on drug exposure and half-life periods of inhalants and injections, the polypeptide coupled drug retains antiviral activity of polypeptide and phlegm eliminating / respiratory tract regulating functions of ambroxol, the drug exposure is increased, and the half-life period is prolonged.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an oral instant film agent of ambroxol or hydrochloride thereof and a preparation method of the oral instant film agent. The oral instant film agent comprises the following components: an active component, a film forming material, a plasticizer and a taste masking agent, and the active component is ambroxol or hydrochloride thereof; the film-forming material comprises hydroxypropyl methylcellulose E5, hydroxypropyl methylcellulose E15 and xanthan gum, and the weight ratio of the film-forming material to the active component (calculated as ambroxol) is (2-5.5): 1. In order to mask the taste of the active components, the taste masking agent in the formula of the oral instant film is relatively high, and the good film-forming property and taste of the oral instant film are ensured by selecting and compounding three film-forming materials and using the pH regulator. The oral cavity instant film can be rapidly disintegrated and dissolved in the oral cavity, is good in taste and high in drug release speed, and can take effect rapidly.

The application provides an ambroxol oral dissolving film composition, a preparation method and application thereof. The ambroxol oral dissolving film composition comprises an active drug, a film forming material and a taste masking agent, and the active drug is 2-amino-3,5-dibromo-N-(trans-4-hydroxycyclohexyl) benzylamine and / or a pharmaceutically acceptable salt thereof, for example, ambroxol hydrochloride. The ambroxol oral dissolving film composition provided by the application has the advantages of thin thickness, good taste, stable properties, immediate dissolution in the oral cavity without drinking water, and fast oral absorption speed. Moreover, the ambroxol oral dissolving film composition has the advantages of simple process, high drug loading, good drug content uniformity, and good market prospect.

This invention relates to an ambroxol oral solution. Specifically, this invention provides an ambroxol oral solution comprising ambroxol hydrochloride, clenbuterol hydrochloride, sucralose, mannitol, trehalose, hydroxyethyl cellulose, citric acid, sodium citrate, sodium bisulfite, glycine, glycerol, and water. The ambroxol oral solution of this invention effectively improves bitterness and its residue, has an excellent taste, and also exhibits excellent stability under light, high temperature, and high humidity, thus providing excellent storage and transportation stability and ensuring quality and safety.

The invention relates to a preparation method of ambroxol hydrochloride and an intermediate thereof, in particular to a preparation method of a structure shown in a formula II and a method for further preparing ambroxol hydrochloride. The ambroxol hydrochloride is obtained by taking o-aminobenzaldehyde as an initial raw material and sequentially carrying out three-step reaction of reductive amination, bromination and salification. The preparation method provided by the invention is a brand new technical route and is not reported in any literature and patent. According to the method, the yield of the product can be greatly improved, and the method is suitable for industrial production.

To provide treatment of glycogen storage disease (GSD).SOLUTION: The present invention relates to a kit of parts comprising (i) a pharmacological chaperone or a pharmaceutically acceptable salt thereof and (ii) a therapeutic acid alpha glucosidase (GAA) polypeptide or a nucleic acid molecule encoding a therapeutic GAA polypeptide, wherein the pharmacological chaperone is 1-deoxynojirimycin (DNJ) or a derivative thereof and Ambroxol (ABX) or a derivative thereof.SELECTED DRAWING: None

The present application provides a kind of antitussive and expectorant medicine, by adding flurbiprofen to traditional strong loquat, in addition to the anti-inflammatory effect of flurbiprofen, it can also significantly improve the antitussive and expectorant efficacy of traditional strong loquat; Patients do not need to take other expectorant drugs at the same time, such as ambroxol, etc., improve the compliance of cough and phlegm patients for drugs, and show obvious advantages in clinic.

The present invention relates to analogs of ambroxol and related compounds, compositions comprising the analogs of ambroxol and / or related compounds, and methods of preventing and / or treating various diseases and medical conditions by administering the analogs of ambroxol and related compounds.

The utility model discloses an ambroxol hydrochloride oral solution filtering and stirring device which comprises a stirring box, the inner wall of the stirring box is rotationally connected with a driving rod through a sealing bearing, stirring blades are installed below the outer wall of the driving rod, a feeding port is formed in the top of the stirring box, a discharging valve is installed at the bottom of the stirring box, and a discharging port is formed in the bottom of the stirring box. And a cleaning structure is arranged above the stirring blades and comprises a screen. The utility model relates to the technical field of solution production equipment, through the cooperation of a screen, a fixing plate and a supporting plate, the screen is placed between the supporting plate and a pressing plate, after the screen is installed, a driving rod is used for driving a strip box to rotate, the screen can rotate around the driving rod, and under the driving of a transmission structure, the screen can rotate, so that the production efficiency is improved. Sediments in the oral liquid are filtered in advance, and the situation that excessive sediments are accumulated on the filter screen at the bottom in the subsequent filtering process, and the filtering effect is affected is avoided.

In certain embodiments, a liquid formulation for oral administration is disclosed, the liquid formulation comprising an amphiphilic material and ambroxol, or a pharmaceutically acceptable salt thereof.

1. The name of the design product: packaging box (ambroxol hydrochloride oral solution). 2. The use of the design product: used for the outer packaging of the product. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: unfolded state reference drawing.

A method for purifying a crude flavor or perfumery or cosmetic ingredient or intermediate, for example crude (−)-Ambrox, comprising a number of washing steps, the products of said method, and uses of said product.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an ambroxol hydrochloride oral solution and a preparation process thereof, and the preparation process comprises the following steps: heating purified water to 60-80 DEG C, adding sorbitol and L-cysteine into the purified water, stirring and dissolving for 10-30 minutes, adding hydroxyethyl cellulose, uniformly dispersing, and cooling to 48-52 DEG C to obtain a first mixed solution; adding ambroxol hydrochloride, benzoic acid and glycerol into the first mixed solution, stirring until the ambroxol hydrochloride, benzoic acid and glycerol are completely dissolved, finally adding essence, and uniformly mixing; and finally, fixing the volume to a set volume by adopting purified water. According to the preparation method disclosed by the invention, through collaborative optimization of dual effects of L-cysteine and a specific feeding sequence, even if the content of sorbitol reducing sugar is greater than 0.3%, the content of an impurity B can still be controlled to be less than or equal to 0.3%, the content of an impurity F can still be controlled to be less than or equal to 0.2%, the deviation between the content of related substances and a reference preparation is less than or equal to + / -0.3%, and the stability is excellent.

To provide a new and improved method for making (-)-Ambrox.SOLUTION: Provided is a process for preparing (-)-Ambrox or a mixture including (-)-Ambrox, the process including enzymatically converting a mixture of homofarnesol isomers into (-)-Ambrox or a mixture including (-)-Ambrox using an SHC / HAC enzyme variant, wherein the SHC / HAC enzyme variant has at least about 70% identity to a specific sequence and has an amino acid modification at a specific position.SELECTED DRAWING: None

An object of the present invention is to provide a pharmaceutical composition that contains loxoprofen or a salt thereof and ambroxol or a salt thereof, while suppressing the decrease in the content of ambroxol or a salt thereof over time. Another object of the present invention is to provide an excellent pharmaceutical composition that contains loxoprofen or a salt thereof and ambroxol or a salt thereof, while suppressing changes in appearance. [Solution] A pharmaceutical composition characterized by containing (A) loxoprofen or a salt thereof, (B) ambroxol or a salt thereof, and (C) noscapine or a salt thereof.

1. The name of the design product: packaging box (ambroxol oral solution). 2. The use of the design product: the design is used for packaging medicines. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: perspective view.

This invention discloses a human olfactory receptor-derived peptide and a biosensor for monitoring ambroxol, belonging to the field of biosensors. Existing methods for detecting ambroxol are cumbersome and costly, and traditional sensing materials have poor selectivity. The amino acid sequence of the derived peptide of this invention is shown in SEQ ID NO: 2. The biosensor includes an Al₂O₃ substrate, 14 pairs of gold interdigitated electrodes, and the electrodes are modified with a single-walled carbon nanotube conductive layer, with the carbon nanotubes covalently linked to the derived peptide. This sensor specifically recognizes ambroxol, shows no significant response to 12 interfering substances, has a detection limit of 50 ppb, an effective detection range of 50 ppb to 5 ppm, and exhibits good stability and adaptability to temperature and humidity. This invention has great practical application potential in the quality control of the ambroxol-related industry.

This invention proposes a compound ambroxol sustained-release microsphere and its preparation method. The compound ambroxol sustained-release microsphere comprises ambroxol hydrochloride, clenbuterol hydrochloride, and a cellulose ester sustained-release material, effectively controlling the dissolution differences between ambroxol hydrochloride and clenbuterol hydrochloride, enabling simultaneous and stable release of both drugs and avoiding efficacy fluctuations due to different release rates. Furthermore, the microsphere utilizes a hot-melt extrusion process, ensuring uniform dispersion of the two active pharmaceutical ingredients within the sustained-release material, thus resolving the uniformity issue caused by low clenbuterol hydrochloride content. The preparation process requires no organic solvents, eliminating solvent residues and preventing degradation or reactions of the active pharmaceutical ingredients in solvents, thereby improving product stability.

The present invention provides an orally disintegrating ambroxol film composition, its preparation method, and use. The orally disintegrating ambroxol film composition comprises an active drug, a film-forming material, and a flavoring agent, where the active drug is 2-amino-3,5-dibromo-N-(trans-4-hydroxycyclohexyl)benzylamine and / or its pharmacologically acceptable salt, such as ambroxol hydrochloride. The orally disintegrating ambroxol film composition according to the present invention has the advantages of being thin, pleasant to the taste, stable, instantly dissolving in the oral cavity without the need for water, and having a fast oral absorption rate. Furthermore, the orally disintegrating ambroxol film composition is simple to process, has a high drug loading, and has good drug content uniformity, making it a promising market.

This invention belongs to the field of organic synthesis technology and provides a method for preparing a key intermediate of ambroxol hydrochloride. The method includes the following steps: methyl 2-aminobenzoate reacts with a brominating reagent under the action of an initiator to generate methyl 2-amino-3,5-dibromobenzoate via a bromination reaction; subsequently, methyl 2-amino-3,5-dibromobenzoate is reduced to 2-amino-3,5-dibromobenzyl alcohol in a reduction system; finally, under the action of an oxidizing agent, 2-amino-3,5-dibromobenzyl alcohol is further oxidized to form the target compound 2-amino-3,5-dibromobenzaldehyde. The optimized process has mild reaction conditions, conforms to green and environmentally friendly principles, significantly improves route safety, uses inexpensive and readily available raw materials, and achieves high product yield and purity, making it suitable for industrial production.